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Introduction
Breast cancer is one of the leading causes of cancer-related 
mortality in women worldwide. Significant progress has 
been made in the diagnosis and treatments of breast cancer, 
but the clinical outcomes of patients remain discouraging 
(1,2). Despite improvements in diagnostic techniques and 
awareness of screening, patients with distant metastasis at 
diagnosis (de novo stage IV breast cancer) still have a poor 
prognosis. Reportedly, de novo stage IV disease accounts for 
approximately 10% of breast cancers (3,4).
With the development of systemic therapies, the 
outcomes of breast cancer patients have been improving. 
Prolongation of overall survival (OS) has also been 
recognized in patients with metastatic breast cancer (MBC). 
In a French study conducted in 2004, which examined 
724 patients with de novo MBC, 27% of patients during 
diagnosed during the period from 1987 to 1993 survived for 
3 at least years, while the rate was 44% for those diagnosed 
between 1994 and 2000 (5). A more recent report from the 
USA, based on data from the Surveillance, Epidemiology 
and End Results (SEER) registries of the National Cancer 
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Institute, described similar trends. The hazard ratio (HR) 
of OS was 0.81 in the groups diagnosed after 2007 (6). 
The mainstay of management for these patients is systemic 
therapies including chemotherapy, endocrine agents and 
tailored treatments targeting the biological features of their 
tumors (7). Local and metastatic sites respond very similarly 
to systemic therapy. Traditionally, aggressive surgery for 
the primary tumor is not recommended for de novo stage IV 
breast cancer due to lack of evidence supporting the efficacy 
of this approach in patients with advanced disease. However, 
local symptoms such as pain, bleeding, anemia, infection, 
and cachexia can significantly reduce quality of life (QOL) 
and primary surgery offers the possibility of ameliorating 
these local symptoms. Moreover, many retrospective studies 
have found that de novo stage IV breast cancer patients 
undergoing primary surgery may achieve better OS (8). 
Furthermore, worldwide, five prospective randomized 
studies have been launched with the goal of examining the 
efficacy of primary surgery for MBC. We conducted a meta-
analysis of the results of these trials, to evaluate whether 
surgical therapy contributes to OS extension in patients 
with de novo stage IV breast cancer.
Methods
Literature search and study selection
We searched for clinical trials published in electronic 
databases (PubMed, Embase, and the Cochrane databases) 
through December 2018. The key words were “breast 
neoplasms”, “mastectomy” and “the equivalent of stage-
IV breast cancer”. In total, 465 potentially relevant reports 
were identified. 
Our meta-analysis was conducted in accordance with 
the Preferred Reporting Items for Systematic Reviews and 
Meta-analyses (PRISMA) (9).
The following inclusive selection criteria were applied: 
(I) Study population: MBC patients with no prior 
history of breast cancer diagnosis and who had not 
undergone primary surgery.
(II) Study design: studies examining the effect of local 
surgery in MBC patients were collected from 
available databases. Studies published as reviews, 
editorials, letters and comments were excluded.
(III) Outcome measures: OS reported for groups with 
versus without local surgery. 
In the event of the same clinical case appearing in several 
publications, to avoid duplication of information, we 
included only the most informative article or that with the 
longest follow-up period. 
Statistical analysis
Randomized controlled phase III trials (RCT) obtain a 
high level of evidence and the results have high clinical 
relevance. Thus, we conducted a quantitative and qualitative 
meta-analysis to evaluate the OS extension effect of primary 
surgical treatment. However, since not all RCT results are 
as yet available and the number of patients is small, we also 
evaluated the results of retrospective studies by performing 
a separate meta-analysis of RCTs. Both meta-analyses were 
performed using Review Manager 5.3.
Results
Prospective trials
We identified five RCTs designed to evaluate the prognostic 
efficacy of resecting the primary lesion in patients with 
de novo stage IV breast cancer. The five trials evaluated were 
the NCT 00193778 trial from India, the NCT 00557986 
(MF07-01) trial from Turkey, the NCT 01242800 (ECOG 
2108) trial from the USA, the NCT 01015625 (ABCSG-28 
POSITIVE) trial from Austria and the UMIN 000005586 
(JCOG 1017 PRIM-BC) trial from Japan (10-14).
All five trials have completed registration and three have 
reported the results obtained. All of these trials aimed to 
determine whether OS extension is achieved by primary 
surgery in patients with de novo stage IV breast cancer. 
There were some differences in the timing of surgery 
and types of systemic therapy administered. Three of the 
five trials examined meta-analyzed required initiation of 
systemic therapy prior to randomization, while others 
randomized the patients first, with versus without surgery, 
prior to systemic therapy. The designs of all five studies 
analyzed herein are summarized in Table S1.
The following results were obtained in the three RCTs 
reported to date. 
Indian trial (NCT 0019377) 
This was a single-institution RCT conducted at the Tata 
Memorial Cancer Institution in Mumbai. Patients were 
registered from 2005 to 2012. In this trial, the study protocol 
was that patients first received chemotherapy, consisting 
primarily of six cycles of anthracycline-based chemotherapy. 
Just 5% of patients also received a taxane. If a specific 
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treatment effect was achieved, the patients were randomized 
into either the surgery or the non-surgery group. Initially, 
716 patients were registered. Of the 716 patients, 440 
showed a response to chemotherapy, but 90 of these were 
excluded for various reasons. Thus, the final count of patients 
eligible for randomization was 350. They were randomized 
to either continue with systemic therapy alone or undergo 
primary local surgery with or without radiation (RT) plus 
continuation of systemic therapy. After randomization, 
173 patients were assigned to receive primary local surgery 
and 177 continued systemic therapy alone. The primary 
endpoint was OS, and secondary endpoints were locoregional 
progression-free survival (PFS), distant PFS and health-
related QOL. 
At the median follow-up of 23 months, 235 had died. 
The median OS was 19.2 months in the surgical group, 
20.5 months in the non-surgical group, not a statistically 
significant difference (HR =1.04. P=0.79) Based on 
the secondary endpoint results, locoregional PFS was 
significantly better in the surgical group (HR =0.16. 
P=0.001), while distant PFS was significantly better in the 
systemic therapy only group (HR =1.42. P=0.012).
MF07-01 trial (NCT 00557986)
Patients were registered from 2008 to 2012. Unlike the 
India trial, the protocol of this trial was to first randomize 
the patients into surgery versus non-surgery groups and 
then compare the prognostic effects of primary local 
surgery. Initially, 312 patients were registered, and 274 
were ultimately evaluable and included in the study. After 
randomization, 138 patients were assigned to receive 
primary local surgery with or without RT. In addition, the 
local surgery required free margins in all cases undergoing 
resection and included axillary dissection if axillary lymph 
node metastasis was detected. The systemic therapy regimen, 
in both groups, was for all patients with hormone receptor-
positive MBC to receive endocrine therapy and all with 
human epidermal growth factor receptor 2 (HER2) positive 
cancer to receive trastuzumab, with a chemotherapy regimen 
consisting primarily of anthracycline-based therapy. The 
primary endpoint was three-year survival, and the OS 
difference between the two groups was 18% (35% in the 
surgical and 17% in the non-surgical group). Secondary 
endpoints were morbidity, locoregional PFS and QOL. 
There was no significant difference in three-year 
survival, the primary endpoint, between the two groups. 
However, the post-analysis evaluation revealed a tendency 
for OS extension, with a median OS of 46 months in the 
surgical group and 37 months in non-surgical group (HR 
=0.66, P=0.005). The secondary endpoint of locoregional 
PFS was 1% in the surgery group and 11% in the non-
surgical group, showing a statistically significant difference 
(P=0.001). 
ABCSG-28 POSITIVE trial (NCT 01015625)
This trial registered patients from 2010 to 2019. The 
protocol was similar to that of the Turkish trial. Patients 
were first randomized to locoregional therapy or systematic 
therapy. Patients in the surgical group received primary 
breast and axillary surgery, with or without RT. After these 
locoregional therapies, systemic therapy was initiated. 
However, even in the non-surgical group, surgery was 
allowed when deemed necessary. The primary endpoint was 
OS, and the secondary endpoints were locoregional PFS 
and distant PFS. The planned number of registrations was 
516, but the trial was terminated after 90 cases had been 
registered, 45 per arm, and the results were then assessed 
and reported. 
The median OS was 34.6 months in the surgical group, 
54.8 months in the non-surgical group, not a statistically 
significant difference (HR =0.691, P=0.267). 
We summarized the results of the three reported RTCs 
examining the effects of surgery on OS. The NCT 0019377 
trial, which registered 350 patients and had a primary 
endpoint of OS, showed no significant difference with 
versus without surgery. The median OS was 19.2 months 
in the surgical and 20.5 months in the non-surgical 
group (HR =1.04. P=0.79). In the ABCSG-28 trial, which 
included 90 patients, a tendency for worsening of OS 
was noted with surgery, but the difference did not reach 
statistical significance. The median OS was 34.6 months 
in the surgical and 54.8 months in the non-surgical group. 
On the other hand, in the MF07-01 trial, 274 patients 
were registered, and a tendency for OS to be extended 
was observed, with median OS being 46 months in the 
surgical and 37 months in the non-surgical group (HR 
=0.66, P=0.005) (Table S2). According to our meta-analysis 
of these three RCTs, surgical treatment of MBC does not 
significantly prolong OS (Figure 1).
The following two trials have completed patient 
enrollment and the results are eagerly anticipated. 
ECOG2108 trial (NCT 0124288) 
Patients were registered from 2011 to 2015. This protocol 
was for patients diagnosed as having de novo stage IV 
breast cancer to first be given systemic therapy. After 
5105Translational Cancer Research, Vol 9, No 8 August 2020
© Translational Cancer Research. All rights reserved.   Transl Cancer Res 2020;9(8):5102-5107 | http://dx.doi.org/10.21037/tcr.2020.01.60
Figure 1 Results of a meta-analysis of 3 prospective studies examining the effect of surgical treatment on OS in patients with metastatic 
breast cancer.
Study or Subgroue 
Experimental 
Events EventsTotal Total Weight M-H, Fixed, 95% Cl M-H, Fixed, 95% Cl 
Control Odds Ratio Odds Ratio 
Atilla Soran et al. 76 138 101 136 51.4% 0.42 [0.26, 0.71] 
1.93 [0.76, 4.90] 
1.10 [0.70, 1.72] 
0.81 [0.60, 1.11] 
0.2               0.5           1             2                  5
Favours [experimental] Favours [control]
Florian Fitzal et al. 35 45 29 45 7.2%
Rajendra Badwe et al. 118 173 117 177 41.4%
100.0%358
247
356
229
Total (95% Cl)
Total events
Heterogeneity: Chi2 =11.30, df = 2 (P =0.004); I2= 82%
Test for overall effect: Z =1.31 (P =0.19) 
4 to 8 months of systemic therapy, patients showing 
treatment effects, such as stable or responsive disease, 
were randomized into surgery and non-surgery groups. 
The initial systemic therapies included endocrine agents, 
chemotherapy and anti-HER2 agents. The surgical group 
received surgery and RT, the standard protocol for local 
disease in a non-metastatic setting. The planned number of 
patients was 880, but registration was closed in 2015 with 
only 383 patients. The primary endpoint was OS at three 
years, and the study was redesigned with power to detect 
a 19% difference between the surgical and non-surgical 
groups. The secondary endpoints were local PFS and QOL.
JCOG 1017 PRIM-BC trial (UMIN 000005586)
Patients were registered from 2011 to 2018. As in the USA 
and India trials, patients initially received systemic therapy 
according to tumor biology for three months. Subsequently, 
those patients in whom treatment achieved an effect were 
randomized into surgery and non-surgery groups. The 
surgical procedures were limited to local tumor resection, 
with neither axillary dissection nor RT. The primary 
endpoint was OS and the secondary endpoints were distant 
PFS, rate of uncontrolled local disease and complications 
from surgery. The planned number of patients was 410 and 
registration was completed when this number was reached. 
The results will be reported in 2022.
Retrospective trials
By performing a literature search according to PRISMA, we 
identified 12 retrospective clinical trials focusing on whether 
or not to remove the primary lesion in patients with de novo 
stage IV breast cancer (15-17). In total, 28,400 patients 
were included in these trials and 14,905 had received local 
surgery. There were variations in the methods and timing of 
surgery among the trials. Axillary management, especially, 
was more difficult to evaluate based on the analysis of 
retrospective studies which do not consistently obtain 
detailed information on this feature of treatment.
Our meta-analysis of the 12 retrospective reports revealed 
that primary surgery for patients with stage IV breast cancer 
prolonged OS (HR: 0.65, P<0.00001) (Figure 2).
Discussion
Our meta-analysis of prospective studies, RCTs, yielded 
results opposite those of retrospective studies. From the 
viewpoint of the strength of evidence, the RCT results 
merit greater emphasis. The retrospective trials have several 
inherent biases, including those reflecting patient age, 
the timing of surgery, the status of cancer metastasis, the 
eligibility criteria applied and so on. These trials could not 
be analyzed in detail or with sufficient accuracy. There is a 
high possibility that the MBC patients for whom doctors 
deemed surgery to be necessarily had distant metastases, 
with surgery having a good local effect on symptoms while 
not impacting OS. In addition, in retrospective studies 
especially, the applications of RT varied markedly. The 
effect of locoregional RT for MBC was demonstrated in two 
studies (18,19). Le Scodan et al. reported that MBC patients 
who received locoregional RT alone showed significantly 
better OS than those who did not (HR =0.7). Nguyen et al. 
reported that there was a significant five-year OS advantage 
in those undergoing locoregional RT as compared to the 
group without RT (P<0.001). RT might also contribute to 
better OS.
However, the three reported RCTs had limitations, such 
that the results must be interpreted with caution. 
First, the timing of breast surgery differed among the 
trials. In the Indian trial (NCT 00193778), the patients 
received prescribed systemic therapy and were subsequently 
randomized to the surgery and non-surgery groups. On 
the other hand, in the other two trials (ABCSG-28, MF07-
01), the patients were initially divided into surgery or non-
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surgery groups and then received systemic therapies.
Second, in the trial from India (NCT 00193778 trial), 
there were very few systemic treatments after randomization 
as compared to industrialized nations. Furthermore, there 
was a lack of standard systemic treatments tailored to cancer 
biology, such as hormonal, chemotherapeutic and targeting 
agents (e.g., trastuzumab). Consequently, the PFS and OS 
in this trial were shorter than in the other two trials. The 
short PFS in the surgical group after randomization may 
have been due to the lack of effective systemic treatment. 
Third, on the MF07-01 trial (NCT 00557986), the 
randomization assignment factors may not have been 
appropriate. For this reason, patients with triple-negative 
type breast cancer, which is considered to have a poor 
prognosis, were more numerous in the non-surgery group. 
Moreover, the originally configured endpoint might not 
have been appropriate, since the overall survival rate was 
the originally planned endpoint, rather than OS itself. The 
method applied for diagnosing metastasis may also have 
produced ambiguous results as established guidelines were 
lacking.
Fourth, in the trial from Europe (ABCSG-28 trial), the 
number of participants was considerably less than planned. 
The planned number was 516 but only 90 patients were 
actually enrolled. As such, inadequate statistical power may 
account for the lack of a significant difference. 
For these reasons, patient backgrounds vary markedly 
among these RCTs. This meta-analysis detected no effect 
of surgery on the OS of breast cancer patients with stage IV 
disease. We eagerly await the results of the two remaining 
RCTs (JCOG1017 and ECOG2108 trial).
Conclusions
Our meta-analysis of the three RCTs reported to date, 
detected no significant of effect of primary surgery on 
the OS of patients with de novo stage IV breast cancer. 
Unfortunately, data on the effects of early surgery for the 
prevention of local symptoms are as yet insufficient. We 
must always carefully weigh the risks and benefits of surgical 
treatments. We await the results of the two-remaining 
ongoing RCTs (ECOG 2108 and JCOG 1017). These trials 
are anticipated to resolve current controversies and provide 
information useful for managing MBC patients.
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India NTC00193778 2005–2013 716 (350) De novo Stage IV Systemic chemotherapy (6–8 cycles) → objective response → 
randomized locoregional treatment or not → only luminal type 
received endcrine therapy
Bp/BT + Ax ±RT OS LPFS, DPFS, QOL
Turkey NCT00557986 
(MF07-01)
2007–2012 274 De novo Stage IV Randomized locoregional therapy or not → systemic therapy Bp/BT + Ax ±RT OS LPFS, morbidity, QOL
Austria NCT01015625 
(ABCSG 28)
2011–2015 90 De novo Stage IV Randomized locoregional therapy or not → systemic therapy Bp/BT + SNB(→Ax) ±RT OS LPFS, DPFS
USA NCT01242800 
(ECOG2108)
2011–2015 368 (258) De novo Stage IV Systemic therapy (4–8 months) → objective response → randomized 
locoregional treatment or not → continue systemic therapy
Bp/BT + SNB(→Ax) ±RT OS LPFS, QOL
JAPAN UMIN000005586 
(JCOG1017)
2011–2018 570 (407) De novo Stage IV Systemic therapy (2 months)→ objective response → randomized 
locoregional treatment or not → continue systemic therapy
Bp/BT OS LPFS, DPFS, proportion of 
uncontrolled local tumor
Table S2 Results of the three reported prospective trials
Study
Randomized 
number
The number of patients Median observation 
period
OS Distant PFS Local PFS
Surgery Non-surgery Non-surgery Surgery HR (P value) Non-surgery Surgery HR (P value) non-surgery Surgery HR (P value)
India 350 173 177 23 19.2 20.5 1.04 (P=0.79) 11.3 19.8 1.42 (P=0.012) NA 18.2 0.16 (P<0.0001)
Turkey 274 138 136 46 37 0.66 (P=0.005)
Austria 90 45 45 37.5 34.6 54.8 0.69 (P=0.267) 13.9 29 0.598 (P=0.067)
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